



C4Diagnostics Appoints Thomas TRAN as Managing Director

March 2, 2021, Marseille, FRANCE - C4Diagnostics, a French biotech developing innovative In Vitro Diagnostic tests for infectious diseases, announced today the appointment of Thomas Tran, MBA, as Managing Director. His long-standing experience in the In Vitro Diagnostic Industry is a key asset to structure C4Diagnostics' activities as the company is scaling-up and deploying its pipeline of products and services.

In his role as Managing Director, Thomas will contribute to the structuration of C4Diagnostics activities and portfolio of high-performance and rapid IVD tests for infectious diseases. In a close tandem work with Younes Lazrak, MBA (CEO and founder), Thomas' responsibilities will include executing the ambitious strategic plan of C4Diagnostics, managing a team of thirty people and overseeing cross-department activities in a context of accelerated growth.

Thomas is a former graduate from ESSEC business school and has more than 20 years of experience in the *in vitro* diagnostics industry where he successfully fulfilled various key management roles within the Top 5 companies of the industry. Prior to joining C4Diagnostics, Thomas was Senior Regional Sales Europe at Beckman Coulter where he developed profitable revenue growth and contributed to business planning. Before this he was Business Development Director at Diagnostica Stago to support the company's growth and expansion worldwide, then Corporate Marketing Segment Manager at Horiba Medical where he defined and drove the implementation of the global marketing plan. He is a skilled entrepreneur who has successfully endorsed Sales, Business Development and Marketing positions at a management level. He also bares an extensive network within the medical device and in vitro diagnostics ecosystem.

"After 20 years of experience with major diagnostic companies, I am proud to take on the management of such an ambitious start-up as C4Diagnostics. We have strong aspirations for the IVD sector. We believe high-performance and rapid IVD tests for infectious diseases such as ours, are the leverage we need to address the problem of anti-microbial resistance," stated Thomas Tran, Managing Director at C4Diagnostics.

"We believe the success of a company relies on its people and Thomas is a great addition to our team. He is taking up as Managing Director at a turning-point in our development. His vision and knowledge of the in vitro diagnostics industry and his managing skills are key to push our business further," commented Younes Lazrak, CEO at C4Diagnostics.

About C4Diagnostics

C4Diagnostics is a French-based biotech specialized in the development of *in vitro* diagnostic (IVD) tests for human infectious diseases for hospital and medical labs. These innovative tests combine great sensitivity and rapidity: three to five times faster than conventional approaches, simple to implement and with performance identical to traditional IVD tests. Its pipeline of products currently focuses on the diagnosis of Covid-19 (C4Covid-19), Legionnaires' Disease (C4Legio-LFA), urinary tract infections (C4UTI) and antimicrobial susceptibility tests (C4AST).

In addition, C4Diagnostics provides a service activity, called C4Services, for the detection of SARS-CoV-2 virus in the environment (wastewater, air, surface) and has supported several Covid-19 surveillance and prevention campaigns during the pandemic.

1



With its rapid and highly sensitive IVD tests, C4Diagnostics ambitions to become one of the main actors in the diagnosis of human infectious diseases field, by giving healthcare professionals sensible diagnostic information in a timely manner and help them reduce misuse of antibiotics.

www.C4Diagnostics.com

Press contacts

Ophelie Philipot Strategy & Communication Manager +33 (0)6 70 07 87 47 Ophelie.Philipot@C4Diagnostics.com

